Lilly's 14th acquisition of the year is a little-known blood cancer biotech
Eli Lilly has been on a shopping spree this year thanks to its GLP-1-driven revenue, and its 14th acquisition of 2026 is in cancer, the domain of expertise for the pharma's head ...
comments(0)
5-min edit window · permanent after that